Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis

Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis

Abstract Background Cisplatin (CDDP)-induced nephrotoxicity is the most important complication of CDDP treatment. 5-Hydroxytryptamine type 3 receptor antagonists (5-HT3RAs) are widely used to prevent chemotherapy-induced nausea and vomiting (CINV). However, in patients with the triple antiemetic (ne...

Full description

Bibliographic Details
Main Authors: Miho Takemura, Kenji Ikemura, Masayoshi Kondo, Fumihiro Yamane, Mikiko Ueda, Masahiro Okuda
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Cisplatin
Nephrotoxicity
Chemotherapy-induced nausea and vomiting
5-hydroxytryptamine type 3 receptor antagonist
Palonosetron
Online Access:https://doi.org/10.1186/s40780-022-00252-z

Internet

https://doi.org/10.1186/s40780-022-00252-z

Similar Items